2023

5th Annual Multidisciplinary Uro-oncology Congress

5thAnnual Multidisciplinary Uro-oncology Congress 2023

Espinas Palace Hotel, (6th-8th September 2023) -(15 th-17th Shahrivar 1402)

<u>"Scientific Programme"</u>

First day: Wednesday –15th Shahrivar ,1402 (6th September, 2023)-(Tehran GMT+3:30) (Morning)

 $(Palace\ Hall\)$

Official Opening	
Quran Recitation, National Anthem, Inauguration	8:00- 8:15

First day: Wednesday –15th Shahrivar ,1402 (6th September, 2023)-(Tehran GMT+3:30) (Morning) (Palace Hall)

	Session I: Localized Prostate Cancer				
Time	Time 8:15-8:30		Prostate cancer - Prime time for smart screening		
8:15- 10 :40					
		Debate: 8:30-9:00	PSMA-PET in local evaluation of the prostate for active surveillance? Debater 1: Yes Debater 2: No		
		Panel discussion: 9:00-10:00	 Case Presentation How to assess men with familial prostate cancer? Modern Imaging in Prostate Cancer: Do We Treat Patients, or Their Scans? What is the best way of risk stratification before biopsy? 		
		10:00-10:15	Role of RP in Advanced prostate cancer		
		10:15-10:30	Genetic Testing in prostate Cancer Management		



(Morning) (Palace)

Opening Ceremony	Time 10:30-10:40	
	Break	10:40 -11:15



(Morning) (Palace)

	Session II: Prostate Cancer					
	Time 11:15-13:15 High risk/Very high risk (T3- 4/N1) Prostate cancer	Panel discussion:				
		11:15-12:30	Moderator (Case presentation)			
11.13-13.13			Role of Surgery			
	Moderator:		Role of EBRT			
	Wioderator.		Role of Neoadjuvant Hormonal manipulation			
			• LuTectomy			



(Morning) (Palace)

12:30-13:15	 Thematic Session When and how to stage? PARP inhibitors: For which mutations and when? Optimal treatment sequencing in the area of triplet therapies for hormone-sensitive disease. What are the best predictive factors for successful treatment with Lu PSMA? 		
Is precision medicine possible in patients with mCRPC? Moderator:			
Pray & Launch		13:15-14:15	



Session III: Prostate Cancer, Testis cancer			
Debate:	14:15-14:45	Oligoprogressive disease: Does this entitiy exist? Debater 1: Yes (Metastatic Directed Therapy) Debater 2: No (Systemic Therapy)	
Moderator Testis Cancer GCT	Panel discussion:	 MicroRNA-371a-3p as a blood-based biomarker in testis cancer Testicular microlithiasis Small testicular lesions Oncofertility 	



(Afternoon) (Palace)

Time 15:45-16:00	Is artificial intelligence (AI) in urology ready for prime time?
16:00-17:00 Therapeutic options in non-seminoma, marker-negative stage II Moderator	 Case presentation Close monitoring RPLND Chemotherapy



Second day: Thursday -16th Shahrivar,1402 (7th September, 2023)- (Tehran GMT+3:30) (Morning) (Palace)

	Session I: Bladder Cancer				
Time 08:15-10:00		08:15-08:30	large Survey in Bladder Cancer		
		Debate: 08:30-09:00	Healthy patient with very high risk NMIBC (EAU22 category): What is best treatment? Does variant histology change your recommendation? Debater 1 Intravesical therapy is the best option Debater 2 Upfront radical cystectomy is best		
	Moderator:	Panel: 09:00-10:00	Is there a role for local therapy to the bladder in patients with oligometastatic disease? • Case presenter • PET imaging for urothelial cancer: FDG and beyond • Systemic therapy is sufficient and optimal Local therapy to bladder should be offered		



Second day: Thursday –16th Shahrivar,1402 (7th September, 2023)- (Tehran GMT+3:30) (Morning) (Palace)

10:00-10:30	In young patients, is prostate-sparing radical cystectomy a safe option for MIBC? Debater 1 No, prostate sparing Debater 2 Prostate sparing	
	Break	10:30 – 11:00



Second day: Thursday –16th Shahrivar,1402 (7th September, 2023)- (Tehran GMT+3:30) (Morning) (Palace)

	Session II: Bladder Cancer					
Time 11:00-12:00	Moderator:	 Case presentation Orthotopic neobladder vs. abdominal urinary diversion: How to balance patients' preference with the risk of urethral recurrence and pelvic recurrence? Stoma siting Treatment of sexual dysfunction Treatment of urinary incontinence 				
12:00-13:00		Acknowledgement	 Mentors in Uro-oncology. Industry Partners Taking memorable group photo. 			

13:00-14:30 Pra	3:00-14:30 Pray & Launch					
		Session III: Penile Cancer				
Time 14:30-15:30	Locally advanced node positive penile cancer, what to do? Moderator:	 Case presentation Neoadjuvant systemic treatment Surgical options Definitive chemoradiation therapy Role of Ilioinguinal LND 				
15:30-15:45	Lecture:	Ethical considerations in the treatment of End-Stage patients				
15:45-16:45	Panel: Moderator:	GU Malignacies in children.				



Third day: Friday –17th Shahrivar, 1402 (8th September, 2023) (Palace Hall) (Morning)

	Session I: Kidney Cancer					
Time 08:15-10:00 08:15-0		Role of neoadjuvant or adjuvant systemic chemotherapy radical nephroureterectomy	Debater 1 : Neoadjuvant Debater 2 : Adjuvant			
	08:30-09:00 Should deferred cytoreductive nephrectomy be performed in primary metastatic RCC after response to immune check point inhibitors?					
	RCC with Tumor Thrombus in the IVC	 Role of Open Surgery Role of Laparascopic surgery The Impact of Immunotherapy on the Level of IVC Tumor Thrombus Impact of Venous Tumor Thrombus Consistency (Solid vs Friable) Impact of Histologic Subtype on Cancer-specific Survival 				

10:00-10:30 Break



Third day: Friday –17th Shahrivar, 1402 (8th September, 2023) (Morning)

Session II: Forensic Medicine in Urology	
Time	Forensic Medicine in Urology.
10:30-11:30	Moderator